Patents by Inventor Mariana Marin

Mariana Marin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for identifying inhibitors
    Patent number: 7220554
    Abstract: Vif binds to APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions. Vif contains two domains, one that binds APOBEC3G and another with a conserved SLQ(Y/F)LA motif that mediates APOBEC3G degradation by a proteasome-dependent pathway. Provided herein are methods of exploiting these discoveries to develop compounds useful to inhibit Vif degradation of APOBEC3G, and thereby inhibit viral infection and/or replication.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: May 22, 2007
    Assignee: Oregon Health and Science University
    Inventors: David Kabat, Mariana Marin, Susan L. Kozak, Kristine M. Rose
  • Methods for identifying inhibitors
    Publication number: 20040234956
    Abstract: Vif binds to APOBEC3G and induces its rapid degradation, thus eliminating it from cells and preventing its incorporation into HIV-1 virions. Vif contains two domains, one that binds APOBEC3G and another with a conserved SLQ(Y/F)LA motif that mediates APOBEC3G degradation by a proteasome-dependent pathway. Provided herein are methods of exploiting these discoveries to develop compounds useful to inhibit Vif degradation of APOBEC3G, and thereby inhibit viral infection and/or replication.
    Type: Application
    Filed: May 3, 2004
    Publication date: November 25, 2004
    Applicant: Oregon Health & Science University
    Inventors: David Kabat, Mariana Marin, Susan L. Kozak, Kristine M. Rose
  • Encapsulated cells producing antibodies
    Patent number: 6426088
    Abstract: The present invention relates to capsules encapsulating antibody-producing cells, and to use of such capsules and encapsulated cells, respectively, for implantation in vivo for long term delivery or sustained delivery of antibodies of therapeutic interest.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: July 30, 2002
    Assignees: Bavarian Nordic Research Institute, Centre National de la Recherche Scientifique
    Inventors: Marc Piechaczyk, Mireia Pelegrin, Mariana Marin, Robert Saller, Brian Salmons